Aptamer Nanomedicine for Cancer Therapeutics: Barriers and Potential for Translation

Pathogen Recognition and Innate Immunity

Akira, S., Uematsu, S., & Takeuchi, O. (2006) · Cell · doi:10.1016/j.cell.2006.02.015 · Cited by 11,952

Systematic Evolution of Ligands by Exponential Enrichment: RNA Ligands to Bacteriophage T4 DNA Polymerase

Tuerk, C., & Gold, L. (1990) · Science · doi:10.1126/science.2200121 · Cited by 10,405

In vitro selection of RNA molecules that bind specific ligands

Ellington, A. D., & Szostak, J. W. (1990) · Nature · doi:10.1038/346818a0 · Cited by 9,812

The biology of VEGF and its receptors

Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591

Recent advances with liposomes as pharmaceutical carriers

Torchilin, V. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1632 · Cited by 5,282

PLGA-based nanoparticles: An overview of biomedical applications

Danhier, F., Ansorena, E., Silva, J. M., Coco, R., Le Breton, A., & Préat, V. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.01.043 · Cited by 3,806

Poly(ethylene glycol) in Drug Delivery: Pros and Cons as Well as Potential Alternatives

Knop, K., Hoogenboom, R., Fischer, D., & Schubert, U. S. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.200902672 · Cited by 3,533

Delivering nanomedicine to solid tumors

Jain, R. K., & Stylianopoulos, T. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.139 · Cited by 3,180

Transport properties of two finite armchair graphene nanoribbons

Rosales, L., & González, J. W. (2013) · Nanoscale Research Letters · doi:10.1186/1556-276x-8-1 · Cited by 1,956

Aptamer-Based Multiplexed Proteomic Technology for Biomarker Discovery

Gold, L., Ayers, D., Bertino, J., Bock, C., Bock, A., Brody, E. N., Carter, J., Dalby, A. B., Eaton, B. E., Fitzwater, T., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015004 · Cited by 1,754

Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo

Farokhzad, O. C., Cheng, J., Teply, B. A., Sherifi, I., Jon, S., Kantoff, P. W., Richie, J. P., & Langer, R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601755103 · Cited by 1,663

Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease

Ng, E. W. M., Shima, D. T., Calias, P., Cunningham, E. T., Guyer, D. R., & Adamis, A. P. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1955 · Cited by 1,588

Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation

Ganz, T. (2003) · Blood · doi:10.1182/blood-2003-03-0672 · Cited by 1,544

Aptamers evolved from live cells as effective molecular probes for cancer study

Shangguan, D., Li, Y., Tang, Z., Cao, Z. C., Chen, H. W., Mallikaratchy, P., Sefah, K., Yang, C. J., & Tan, W. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602615103 · Cited by 1,516

SELEX—A (r)evolutionary method to generate high-affinity nucleic acid ligands

Stoltenburg, R., Reinemann, C., & Strehlitz, B. (2007) · Biomolecular Engineering · doi:10.1016/j.bioeng.2007.06.001 · Cited by 1,430

Age-related macular degeneration

Jager, R. D., Mieler, W. F., & Miller, J. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0801537 · Cited by 1,379

F c RECEPTOR BIOLOGY

Daëron, M. (1997) · Annual Review of Immunology · doi:10.1146/annurev.immunol.15.1.203 · Cited by 1,227

Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor

SADLER, J. E., BUDDE, U., EIKENBOOM, J. C. J., FAVALORO, E. J., HILL, F. G. H., HOLMBERG, L., INGERSLEV, J., LEE, C. A., LILLICRAP, D., MANNUCCI, P. M., et al. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.02146.x · Cited by 1,150

Quantum Dot−Aptamer Conjugates for Synchronous Cancer Imaging, Therapy, and Sensing of Drug Delivery Based on Bi-Fluorescence Resonance Energy Transfer

Bagalkot, V., Zhang, L., Levy-Nissenbaum, E., Jon, S., Kantoff, P. W., Langer, R., & Farokhzad, O. C. (2007) · Nano Letters · doi:10.1021/nl071546n · Cited by 1,036

Analytical applications of aptamers

Tombelli, S., Minunni, M., & Mascini, M. (2005) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2004.11.006 · Cited by 1,017

Cell type–specific delivery of siRNAs with aptamer-siRNA chimeras

McNamara, J. O., Andrechek, E. R., Wang, Y., Viles, K. D., Rempel, R. E., Gilboa, E., Sullenger, B. A., & Giangrande, P. H. (2006) · Nature Biotechnology · doi:10.1038/nbt1223 · Cited by 1,002

Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA–PEG nanoparticles

Dhar, S., Gu, F. X., Langer, R., Farokhzad, O. C., & Lippard, S. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809154105 · Cited by 994

Aptamers: An Emerging Class of Therapeutics

Nimjee, S. M., Rusconi, C. P., & Sullenger, B. A. (2005) · Annual Review of Medicine · doi:10.1146/annurev.med.56.062904.144915 · Cited by 937

Development of DNA aptamers using Cell-SELEX

Sefah, K., Shangguan, D., Xiong, X., O'Donoghue, M. B., & Tan, W. (2010) · Nature Protocols · doi:10.1038/nprot.2010.66 · Cited by 918

Liposomal Drug Delivery Systems: An Update Review

Samad, A., Sultana, Y., & Aqil, M. (2007) · Current Drug Delivery · doi:10.2174/156720107782151269 · Cited by 906

Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer

Bates, P. J., Laber, D. A., Miller, D. M., Thomas, S. D., & Trent, J. O. (2009) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2009.01.004 · Cited by 874

Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration

FERRARA, N., DAMICO, L., SHAMS, N., LOWMAN, H., & KIM, R. (2006) · Retina · doi:10.1097/01.iae.0000242842.14624.e7 · Cited by 849

Strategies for advancing cancer nanomedicine

Chauhan, V. P., & Jain, R. K. (2013) · Nature Materials · doi:10.1038/nmat3792 · Cited by 812

MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1

Garzon, R., Liu, S., Fabbri, M., Liu, Z., Heaphy, C. E. A., Callegari, E., Schwind, S., Pang, J., Yu, J., Muthusamy, N., et al. (2009) · Blood · doi:10.1182/blood-2008-07-170589 · Cited by 781

2′-Fluoropyrimidine RNA-based Aptamers to the 165-Amino Acid Form of Vascular Endothelial Growth Factor (VEGF165)

Ruckman, J., Green, L. S., Beeson, J., Waugh, S., Gillette, W. L., Henninger, D. D., Claesson-Welsh, L., & Janjic, N. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.32.20556 · Cited by 744

The pivotal role of the complement system in aging and age-related macular degeneration: Hypothesis re-visited

Anderson, D. H., Radeke, M. J., Gallo, N. B., Chapin, E. A., Johnson, P. T., Curletti, C. R., Hancox, L. S., Hu, J., Ebright, J. N., Malek, G., et al. (2010) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2009.11.003 · Cited by 727

Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers

Gu, F., Zhang, L., Teply, B. A., Mann, N., Wang, A., Radovic-Moreno, A. F., Langer, R., & Farokhzad, O. C. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711714105 · Cited by 715

Aptamers come of age – at last

Bunka, D. H. J., & Stockley, P. G. (2006) · Nature Reviews Microbiology · doi:10.1038/nrmicro1458 · Cited by 695

The role of let-7 in cell differentiation and cancer

Boyerinas, B., Park, S.-M., Hau, A., Murmann, A. E., & Peter, M. E. (2010) · Endocrine-Related Cancer · doi:10.1677/erc-09-0184 · Cited by 669

An Aptamer–Doxorubicin Physical Conjugate as a Novel Targeted Drug‐Delivery Platform

Bagalkot, V., Farokhzad, O. C., Langer, R., & Jon, S. (2006) · Angewandte Chemie International Edition · doi:10.1002/anie.200602251 · Cited by 613

Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors

Dassie, J. P., Liu, X.-Y., Thomas, G. S., Whitaker, R. M., Thiel, K. W., Stockdale, K. R., Meyerholz, D. K., McCaffrey, A. P., McNamara, J. O., & Giangrande, P. H. (2009) · Nature Biotechnology · doi:10.1038/nbt.1560 · Cited by 589

Aptamers: molecular tools for analytical applications

Mairal, T., Cengiz Özalp, V., Lozano Sánchez, P., Mir, M., Katakis, I., & O’Sullivan, C. K. (2008) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-007-1346-4 · Cited by 587

Aptamer-functionalized PEG–PLGA nanoparticles for enhanced anti-glioma drug delivery

Guo, J., Gao, X., Su, L., Xia, H., Gu, G., Pang, Z., Jiang, X., Yao, L., Chen, J., & Chen, H. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.07.004 · Cited by 566

Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen.

Lupold, S. E., Hicke, B. J., Lin, Y. H., & Coffey, D. S. (2002) · PubMed · Cited by 566

Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy

Kolishetti, N., Dhar, S., Valencia, P. M., Lin, L. Q., Karnik, R., Lippard, S. J., Langer, R., & Farokhzad, O. C. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1011368107 · Cited by 565

Self-assembled, aptamer-tethered DNA nanotrains for targeted transport of molecular drugs in cancer theranostics

Zhu, G., Zheng, J., Song, E., Donovan, M., Zhang, K., Liu, C., & Tan, W. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1220817110 · Cited by 546

Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo

Dhar, S., Kolishetti, N., Lippard, S. J., & Farokhzad, O. C. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1011379108 · Cited by 513

RNA aptamers as reversible antagonists of coagulation factor IXa

Rusconi, C. P., Scardino, E., Layzer, J., Pitoc, G. A., Ortel, T. L., Monroe, D., & Sullenger, B. A. (2002) · Nature · doi:10.1038/nature00963 · Cited by 512

Generation of high-affinity DNA aptamers using an expanded genetic alphabet

Kimoto, M., Yamashige, R., Matsunaga, K.-I., Yokoyama, S., & Hirao, I. (2013) · Nature Biotechnology · doi:10.1038/nbt.2556 · Cited by 510

Folding-Based Electrochemical Biosensors: The Case for Responsive Nucleic Acid Architectures

Lubin, A. A., & Plaxco, K. W. (2010) · Accounts of Chemical Research · doi:10.1021/ar900165x · Cited by 506

Discovery and development of anticancer aptamers

Ireson, C. R., & Kelland, L. R. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0172 · Cited by 481

Selection of Aptamers for Molecular Recognition and Characterization of Cancer Cells

Tang, Z., Shangguan, D., Wang, K., Shi, H., Sefah, K., Mallikratchy, P., Chen, H. W., Li, Y., & Tan, W. (2007) · Analytical Chemistry · doi:10.1021/ac070189y · Cited by 479

Cell-Specific Aptamer Probes for Membrane Protein Elucidation in Cancer Cells

Shangguan, D., Cao, Z., Meng, L., Mallikaratchy, P., Sefah, K., Wang, H., Li, Y., & Tan, W. (2008) · Journal of Proteome Research · doi:10.1021/pr700894d · Cited by 465

Molecular Assembly of an Aptamer–Drug Conjugate for Targeted Drug Delivery to Tumor Cells

Huang, Y., Shangguan, D., Liu, H., Phillips, J. A., Zhang, X., Chen, Y., & Tan, W. (2009) · ChemBioChem · doi:10.1002/cbic.200800805 · Cited by 422

PRECLINICAL AND PHASE 1A CLINICAL EVALUATION OF AN ANTI-VEGF PEGYLATED APTAMER (EYE001) FOR THE TREATMENT OF EXUDATIVE AGE-RELATED MACULAR DEGENERATION

THE EYETECH STUDY GROUP (2002) · Retina · doi:10.1097/00006982-200204000-00002 · Cited by 415

DNA Aptamers That Bind to MUC1 Tumour Marker: Design and Characterization of MUC1-Binding Single-Stranded DNA Aptamers

Ferreira, C. S. M., Matthews, C. S., & Missailidis, S. (2006) · Tumor Biology · doi:10.1159/000096085 · Cited by 407

Inhibitory DNA Ligands to Platelet-Derived Growth Factor B-Chain

Green, L. S., Jellinek, D., Jenison, R., Östman, A., Heldin, C.-H., & Janjic, N. (1996) · Biochemistry · doi:10.1021/bi961544+ · Cited by 390

Tumor targeting by an aptamer.

Hicke, B. J., Stephens, A. W., Gould, T. A., Chang, Y.-F., Lynott, C. K., Heil, J., Borkowski, S., Hilger, C. S., Cook, G., Warren, S., et al. (2006) · PubMed · Cited by 384

Reversible Cell‐Specific Drug Delivery with Aptamer‐Functionalized Liposomes

Cao, Z., Tong, R., Mishra, A., Xu, W., Wong, G. C. L., Cheng, J., & Lu, Y. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200901452 · Cited by 372

Biology of Platelet-Derived Growth Factor and Its Involvement in Disease

Alvarez, R. H., Kantarjian, H. M., & Cortes, J. E. (2006) · Mayo Clinic Proceedings · doi:10.4065/81.9.1241 · Cited by 334

DNA aptamer–micelle as an efficient detection/delivery vehicle toward cancer cells

Wu, Y., Sefah, K., Liu, H., Wang, R., & Tan, W. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909611107 · Cited by 330

Tenascin-C Aptamers Are Generated Using Tumor Cells and Purified Protein

Hicke, B. J., Marion, C., Chang, Y.-F., Gould, T., Lynott, C. K., Parma, D., Schmidt, P. G., & Warren, S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m104651200 · Cited by 324

Inhibition of Platelet-Derived Growth Factor B Signaling Enhances the Efficacy of Anti-Vascular Endothelial Growth Factor Therapy in Multiple Models of Ocular Neovascularization

Jo, N., Mailhos, C., Ju, M., Cheung, E., Bradley, J., Nishijima, K., Robinson, G. S., Adamis, A. P., & Shima, D. T. (2006) · The American Journal of Pathology · doi:10.2353/ajpath.2006.050588 · Cited by 322

Discovery and Development of Therapeutic Aptamers

Bouchard, P. R., Hutabarat, R. M., & Thompson, K. M. (2010) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105547 · Cited by 320

Aptamer-Conjugated DNA Icosahedral Nanoparticles As a Carrier of Doxorubicin for Cancer Therapy

Chang, M., Yang, C.-S., & Huang, D.-M. (2011) · ACS Nano · doi:10.1021/nn200693a · Cited by 318

Tumor targeted quantum dot-mucin 1 aptamer-doxorubicin conjugate for imaging and treatment of cancer

Savla, R., Taratula, O., Garbuzenko, O., & Minko, T. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.02.015 · Cited by 314

Expanding the Chemistry of DNA for in Vitro Selection

Vaught, J. D., Bock, C., Carter, J., Fitzwater, T., Otis, M., Schneider, D., Rolando, J., Waugh, S., Wilcox, S. K., & Eaton, B. E. (2010) · Journal of the American Chemical Society · doi:10.1021/ja908035g · Cited by 313

From SOMAmer-based biomarker discovery to diagnostic and clinical applications: a SOMAmer-based, streamlined multiplex proteomic assay

Kraemer, S., Vaught, J. D., Bock, C., Gold, L., Katilius, E., Keeney, T. R., Kim, N., Saccomano, N. A., Wilcox, S. K., Zichi, D., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026332 · Cited by 310

Activatable aptamer probe for contrast-enhanced in vivo cancer imaging based on cell membrane protein-triggered conformation alteration

Shi, H., He, X., Wang, K., Wu, X., Ye, X., Guo, Q., Tan, W., Qing, Z., Yang, X., & Zhou, B. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016197108 · Cited by 301

Aptamer-Based Tumor-Targeted Drug Delivery for Photodynamic Therapy

Shieh, Y.-A., Yang, S.-J., Wei, M.-F., & Shieh, M.-J. (2010) · ACS Nano · doi:10.1021/nn901374b · Cited by 299

Pharmacokinetics and Biodistribution of Novel Aptamer Compositions

Healy, J. M., Lewis, S. D., Kurz, M., Boomer, R. M., Thompson, K. M., Wilson, C., & McCauley, T. G. (2004) · Pharmaceutical Research · doi:10.1007/s11095-004-7676-4 · Cited by 298

Nucleolin-targeting liposomes guided by aptamer AS1411 for the delivery of siRNA for the treatment of malignant melanomas

Li, L., Hou, J., Liu, X., Guo, Y., Wu, Y., Zhang, L., & Yang, Z. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.01.019 · Cited by 289

In vivo anticoagulant properties of a novel nucleotide-based thrombin inhibitor and demonstration of regional anticoagulation in extracorporeal circuits

Griffin, L., Tidmarsh, G., Bock, L., Toole, J., & Leung, L. (1993) · Blood · doi:10.1182/blood.v81.12.3271.3271 · Cited by 285

Aptamer:Toxin Conjugates that Specifically Target Prostate Tumor Cells

Chu, T. C., Marks, J. W., Lavery, L. A., Faulkner, S., Rosenblum, M. G., Ellington, A. D., & Levy, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4583 · Cited by 284

In vivo selection of tumor-targeting RNA motifs

Mi, J., Liu, Y., Rabbani, Z. N., Yang, Z., Urban, J. H., Sullenger, B. A., & Clary, B. M. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.277 · Cited by 269

Aptamer Directly Evolved from Live Cells Recognizes Membrane Bound Immunoglobin Heavy Mu Chain in Burkitt's Lymphoma Cells

Mallikaratchy, P., Tang, Z., Kwame, S., Meng, L., Shangguan, D., & Tan, W. (2007) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m700026-mcp200 · Cited by 268

Unique motifs and hydrophobic interactions shape the binding of modified DNA ligands to protein targets

Davies, D. R., Gelinas, A. D., Zhang, C., Rohloff, J. C., Carter, J. D., O’Connell, D., Waugh, S. M., Wolk, S. K., Mayfield, W. S., Burgin, A. B., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1213933109 · Cited by 256

The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization

Hoellenriegel, J., Zboralski, D., Maasch, C., Rosin, N. Y., Wierda, W. G., Keating, M. J., Kruschinski, A., & Burger, J. A. (2014) · Blood · doi:10.1182/blood-2013-03-493924 · Cited by 242

Aptamer-conjugated and doxorubicin-loaded unimolecular micelles for targeted therapy of prostate cancer

Xu, W., Siddiqui, I. A., Nihal, M., Pilla, S., Rosenthal, K., Mukhtar, H., & Gong, S. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.03.006 · Cited by 223

In vivo SELEX for Identification of Brain-penetrating Aptamers

Cheng, C., Chen, Y. H., Lennox, K. A., Behlke, M. A., & Davidson, B. L. (2013) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2012.59 · Cited by 214

Unlocking biomarker discovery: Large scale application of aptamer proteomic technology for early detection of lung cancer

Ostroff, R., Bigbee, W., Franklin, W., Gold, L., Mehan, M., Miller, Y., Pass, H., Rom, W., Siegfried, J., Stewart, A., et al. (2010) · Nature Precedings · doi:10.1038/npre.2010.4537.1 · Cited by 213

Contrast agents for MRI

Shokrollahi, H. (2013) · Materials Science and Engineering: C · doi:10.1016/j.msec.2013.07.012 · Cited by 211

Exploring Chemical Modifications for siRNA Therapeutics: A Structural and Functional Outlook

Shukla, S., Sumaria, C. S., & Pradeepkumar, P. I. (2010) · ChemMedChem · doi:10.1002/cmdc.200900444 · Cited by 210

Selective delivery of an anticancer drug with aptamer-functionalized liposomes to breast cancer cells in vitro and in vivo

Xing, H., Tang, L., Yang, X., Hwang, K., Wang, W., Yin, Q., Wong, N. Y., Dobrucki, L. W., Yasui, N., Katzenellenbogen, J. A., et al. (2013) · Journal of Materials Chemistry B · doi:10.1039/c3tb20412j · Cited by 199

Nucleic acid aptamers for biosensors and bio-analytical applications

Sefah, K., Phillips, J. A., Xiong, X., Meng, L., Van Simaeys, D., Chen, H., Martin, J., & Tan, W. (2009) · The Analyst · doi:10.1039/b905609m · Cited by 194

Novel HER2 Aptamer Selectively Delivers Cytotoxic Drug to HER2-positive Breast Cancer Cells in Vitro

Liu, Z., Duan, J.-H., Song, Y.-M., Ma, J., Wang, F.-D., Lu, X., & Yang, X.-D. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-148 · Cited by 193

Multivalent RNA aptamers that inhibit CTLA-4 and enhance tumor immunity.

Santulli-Marotto, S., Nair, S. K., Rusconi, C. P., Sullenger, B. A., & Gilboa, E. (2003) · PubMed · Cited by 188

Spiegelmer Inhibition of CCL2/MCP-1 Ameliorates Lupus Nephritis in MRL-(Fas)lpr Mice

Kulkarni, O., Pawar, R. D., Purschke, W., Eulberg, D., Selve, N., Buchner, K., Ninichuk, V., Segerer, S., Vielhauer, V., Klussmann, S., et al. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006121348 · Cited by 187

Automated Modular Synthesis of Aptamer–Drug Conjugates for Targeted Drug Delivery

Wang, R., Zhu, G., Mei, L., Xie, Y., Ma, H., Ye, M., Qing, F.-L., & Tan, W. (2014) · Journal of the American Chemical Society · doi:10.1021/ja4117395 · Cited by 181

Size-Dependent Tumor Penetration and in Vivo Efficacy of Monodisperse Drug–Silica Nanoconjugates

Tang, L., Gabrielson, N. P., Uckun, F. M., Fan, T. M., & Cheng, J. (2013) · Molecular Pharmaceutics · doi:10.1021/mp300684a · Cited by 174

Multifunctional Aptamer-miRNA Conjugates for Targeted Cancer Therapy

Esposito, C. L., Cerchia, L., Catuogno, S., De Vita, G., Dassie, J. P., Santamaria, G., Swiderski, P., Condorelli, G., Giangrande, P. H., & de Franciscis, V. (2014) · Molecular Therapy · doi:10.1038/mt.2014.5 · Cited by 169

A DNA Aptamer Prevents Influenza Infection by Blocking the Receptor Binding Region of the Viral Hemagglutinin

Jeon, S. H., Kayhan, B., Ben-Yedidia, T., & Arnon, R. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m409059200 · Cited by 169

In vivo imaging of inflammation using an aptamer inhibitor of human neutrophil elastase

Charlton, J., Sennello, J., & Smith, D. (1997) · Chemistry & Biology · doi:10.1016/s1074-5521(97)90114-9 · Cited by 163

The effects of the anti-hepcidin Spiegelmer NOX-H94 on inflammation-induced anemia in cynomolgus monkeys

Schwoebel, F., van Eijk, L. T., Zboralski, D., Sell, S., Buchner, K., Maasch, C., Purschke, W. G., Humphrey, M., Zöllner, S., Eulberg, D., et al. (2013) · Blood · doi:10.1182/blood-2012-09-456756 · Cited by 158

CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells

Herrmann, A., Priceman, S. J., Kujawski, M., Xin, H., Cherryholmes, G. A., Zhang, W., Zhang, C., Lahtz, C., Kowolik, C. M., Forman, S. J., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73174 · Cited by 157

Inhibition of von Willebrand factor‐mediated platelet activation and thrombosis by the anti‐von Willebrand factor A1‐domain aptamer ARC1779

Duerschmied, D., Merhi, Y., Tanguay, J., Hutabarat, R. M., GILBERT, J., Wagner, D. D., Schaub, R. G., Diener, J. L., & Lagassé, H. A. D. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03459.x · Cited by 156

Targeting Axl With an High-affinity Inhibitory Aptamer

Cerchia, L., Esposito, C. L., Camorani, S., Rienzo, A., Stasio, L., Insabato, L., Affuso, A., & de Franciscis, V. (2012) · Molecular Therapy · doi:10.1038/mt.2012.163 · Cited by 155

Development of aptamer therapeutics

Bunka, D. H. J., Platonova, O., & Stockley, P. G. (2010) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2010.06.009 · Cited by 153

Derivation of RNA aptamer inhibitors of human complement C5

Biesecker, G., Dihel, L., Enney, K., & Bendele, R. A. (1999) · Immunopharmacology · doi:10.1016/s0162-3109(99)00020-x · Cited by 152

Novel MUC1 Aptamer Selectively Delivers Cytotoxic Agent to Cancer Cells In Vitro

Hu, Y., Duan, J., Zhan, Q., Wang, F., Lu, X., & Yang, X. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031970 · Cited by 149

Epirubicin loaded super paramagnetic iron oxide nanoparticle-aptamer bioconjugate for combined colon cancer therapy and imaging in vivo

Jalalian, S. H., Taghdisi, S. M., Hamedani, N. S., Moosavian, S. A., Lavaee, P., Zandkarimi, M., Ghows, N., Jaafari, M. R., Naghibi, S., Danesh, N. M., et al. (2013) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2013.06.015 · Cited by 147

Aptamer ARC19499 mediates a procoagulant hemostatic effect by inhibiting tissue factor pathway inhibitor

Waters, E. K., Genga, R. M. J., Schwartz, M. C., Nelson, J. A., Schaub, R. G., Olson, K. A., Kurz, J. C., & McGinness, K. E. (2011) · Blood · doi:10.1182/blood-2010-10-311936 · Cited by 143

Current Progress of RNA Aptamer-Based Therapeutics

Zhou, J., Bobbin, M. L., Burnett, J., & Rossi, J. J. (2012) · Frontiers in Genetics · doi:10.3389/fgene.2012.00234 · Cited by 143

Prostate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts

Ni, X., Zhang, Y., Ribas, J., Chowdhury, W. H., Castanares, M. A., Zhang, Z., Laiho, M., DeWeese, T. L., & Lupold, S. E. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45109 · Cited by 143

Late Onset of Ccl2 Blockade with the Spiegelmer mNOX-E36–3′PEG Prevents Glomerulosclerosis and Improves Glomerular Filtration Rate in db/db Mice

Ninichuk, V., Clauß, S., Kulkarni, O. P., Schmid, H., Segerer, S., Radomska, E., Eulberg, D., Buchner, K., Selve, N., Klußmann, S., et al. (2008) · American Journal Of Pathology · doi:10.2353/ajpath.2008.070601 · Cited by 135

Development of universal antidotes to control aptamer activity

Oney, S., Lam, R. T. S., Bompiani, K. M., Blake, C. M., Quick, G., Heidel, J. D., Liu, J. Y.-C., Mack, B. C., Davis, M. E., Leong, K. W., et al. (2009) · Nature Medicine · doi:10.1038/nm.1990 · Cited by 121

Model‐guided design of ligand‐regulated RNAi for programmable control of gene expression

Beisel, C. L., Bayer, T. S., Hoff, K. G., & Smolke, C. D. (2008) · Molecular Systems Biology · doi:10.1038/msb.2008.62 · Cited by 113

In vivo Fluorescence Imaging of Tumors using Molecular Aptamers Generated by Cell‐SELEX

Shi, H., Tang, Z., Kim, Y., et al. (2010) · Chemistry - An Asian Journal · doi:10.1002/asia.201000242 · Cited by 107

Nanoparticle-mediated delivery of siRNA targeting Parp1 extends survival of mice bearing tumors derived from Brca1-deficient ovarian cancer cells

Goldberg, M. S., Xing, D., Ren, Y., Oršulić, S., Bhatia, S. N., & Sharp, P. A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016538108 · Cited by 107

Bovine serum albumin nanoparticles modified with multilayers and aptamers for pH-responsive and targeted anti-cancer drug delivery

Xie, L., Tong, W., Yu, D.-H., Xu, J., Li­, ­., & Gao, C. (2012) · Journal of Materials Chemistry · doi:10.1039/c2jm16831f · Cited by 104

First Clinical Application of an Actively Reversible Direct Factor IXa Inhibitor as an Anticoagulation Strategy in Patients Undergoing Percutaneous Coronary Intervention

Cohen, M. G., Purdy, D. A., Rossi, J. S., Grinfeld, L. R., Myles, S. K., Aberle, L. H., Greenbaum, A. B., Fry, E. T. A., Chan, M. Y., Tonkens, R. M., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.927756 · Cited by 100

The molecular mechanisms of immunomodulation and tolerance induction to factor VIII

Waters, B., & Lillicrap, D. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03538.x · Cited by 97

Aptamer base: a collaborative knowledge base to describe aptamers and SELEX experiments

Cruz-Toledo, J., McKeague, M., Zhang, X., Giamberardino, A., McConnell, E., Francis, T., DeRosa, M. C., & Dumontier, M. (2012) · Database · doi:10.1093/database/bas006 · Cited by 95

Enhancement of Aptamer Microarray Sensitivity through Spacer Optimization and Avidity Effect

Lao, Y., Peck, K., & Chen, L. (2009) · Analytical Chemistry · doi:10.1021/ac801285a · Cited by 93

Dimeric DNA Aptamer Complexes for High-capacity–targeted Drug Delivery Using pH-sensitive Covalent Linkages

Boyacıoğlu, O., Stuart, C. H., Kulik, G., & Gmeiner, W. H. (2013) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2013.37 · Cited by 92

Antisense Effect of Oligodeoxynucleotides with Inverted Terminal Internucleotidic Linkages: A Minimal Modification Protecting against Nucleolytic Degradation

Ortigao, J. F. R., Rösch, H., Selter, H., et al. (1992) · Antisense Research and Development · doi:10.1089/ard.1992.2.129 · Cited by 92

Aptamer-conjugated Mn3O4@SiO2 core–shell nanoprobes for targeted magnetic resonance imaging

Hu, H., Dai, A., Sun, J., Li, X., Gao, F., Wu, L., Fang, Y., Yang, H., An, L., Wu, H., et al. (2013) · Nanoscale · doi:10.1039/c3nr03490a · Cited by 84

Anticancer role of MUC1 aptamer–miR-29b chimera in epithelial ovarian carcinoma cells through regulation of PTEN methylation

Dai, F., Zhang, Y., Zhu, X., Shan, N., & Chen, Y. (2012) · Targeted Oncology · doi:10.1007/s11523-012-0236-7 · Cited by 77

Aptamer-Based Therapeutics: New Approaches to Combat Human Viral Diseases

Shum, K., Zhou, J., & Rossi, J. P. (2013) · Pharmaceuticals · doi:10.3390/ph6121507 · Cited by 75

Synergistic inhibition of lung cancer cell invasion, tumor growth and angiogenesis using aptamer-siRNA chimeras

Lai, W., Wang, W.-Y., Chang, Y.-C., Chang, C.-J., Yang, P., & Peck, K. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2013.12.054 · Cited by 67

A new nucleic acid–based agent inhibits cytotoxic T lymphocyte–mediated immune disorders

Wang, C., Chung, W., Cheng, Y., Ying, N.-W., Peck, K., Chen, Y.-T., & Chung, W. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.04.036 · Cited by 66

Soluble FCγ receptors

Fridman, W. H., Teillaud, J., Bouchard, C., Teillaud, C., Astier, A., Tartour, É., Galon, J., Mathiot, C., & Sautès‐Fridman, C. (1993) · Journal of Leukocyte Biology · doi:10.1002/jlb.54.5.504 · Cited by 65

Modifications Incorporated in CpG Motifs of Oligodeoxynucleotides Lead to Antagonist Activity of Toll-like Receptors 7 and 9

Yu, D. S., Wang, D., Zhu, F., Bhagat, L., Dai, M., Kandimalla, E. R., & Agrawal, S. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900730r · Cited by 64

Identification and characterization of oligonucleotides that inhibit Toll‐like receptor 2‐associated immune responses

Chang, Y.-C., Kao, W., Wang, W.-Y., Wang, W., Yang, R., & Peck, K. (2009) · The FASEB Journal · doi:10.1096/fj.09-129312 · Cited by 59

Materials innovation for co-delivery of diverse therapeutic cargos

Godsey, M. E., Suryaprakash, S., & Leong, K. W. (2013) · RSC Advances · doi:10.1039/c3ra43094d · Cited by 57

Pegaptanib sodium as maintenance therapy in neovascular age-related macular degeneration: the LEVEL study

Friberg, T. R., Tolentino, M., & for the LEVEL Study Group (2010) · British Journal of Ophthalmology · doi:10.1136/bjo.2009.174946 · Cited by 50

Cardiovascular Risk and Antiangiogenic Therapy for Age-related Macular Degeneration

Tuñón, J., Ruiz‐Moreno, J. M., Martín-Ventura, J. L., Blanco‐Colio, L. M., Lorenzo, Ó., & Egido, J. (2009) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2009.02.003 · Cited by 48

Prostate-Targeted Biodegradable Nanoparticles Loaded with Androgen Receptor Silencing Constructs Eradicate Xenograft Tumors in Mice

Yang, J., Xie, S., Huang, Y., Ling, M., Liu, J., Ran, Y., Wang, Y., Thrasher, J. B., Berkland, C. J., & Li, B. (2012) · Nanomedicine · doi:10.2217/nnm.12.14 · Cited by 48

The anti-chemoresistant effect and mechanism of MUC1 aptamer–miR-29b chimera in ovarian cancer

Dai, F., Zhang, Y., Zhu, X., Shan, N., & Chen, Y. (2013) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.07.112 · Cited by 47

Oligodeoxyribonucleotide-Based Antagonists for Toll-Like Receptors 7 and 9

Wang, D., Bhagat, L., Yu, D. S., Zhu, F., Tang, J. X., Kandimalla, E. R., & Agrawal, S. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8014316 · Cited by 43

Protection of HIV Neutralizing Aptamers against Rectal and Vaginal Nucleases

Moore, M. D., Cookson, J., Coventry, V. K., Sproat, B. S., Rabe, L. K., Cranston, R., McGowan, I., & James, W. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.178426 · Cited by 37

NOX-A12: mobilizing CLL away from home

Marasca, R., & Maffei, R. (2014) · Blood · doi:10.1182/blood-2013-12-542480 · Cited by 34

Development and characterization of an aptamer binding ligand of fractalkine using domain targeted SELEX

Waybrant, B., Pearce, T. R., Wang, P., Sreevatsan, S., & Kokkoli, E. (2012) · Chemical Communications · doi:10.1039/c2cc34217k · Cited by 26

Selection of aptamers targeting the sialic acid receptor of hemagglutinin by epitope-specific SELEX

Lao, Y., Chiang, H.-Y., Yang, D., Peck, K., & Chen, L. (2014) · Chemical Communications · doi:10.1039/c4cc03116d · Cited by 26

Measurement of Cetuximab and Panitumumab-Unbound Serum EGFR Extracellular Domain Using an Assay Based on Slow Off-Rate Modified Aptamer (SOMAmer) Reagents

Park, N. J., Wang, X., Diaz, A., Goos, D. M., Bock, C., Vaught, J. D., Sun, W., & Strom, C. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071703 · Cited by 21

Smart nanoparticles for cancer therapy

Sun, L., Liu, H., Ye, Y., Lei, Y., Islam, R., Tan, S., Tong, R., Miao, Y.-B., & Cai, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01642-x · Cited by 1,073

CRISPR/Cas9-based genome editing for disease modeling and therapy: challenges and opportunities for nonviral delivery

Wang, H.-X., Li, M., Lee, C. M., Chakraborty, S., Kim, H.-W., Bao, G., & Leong, K. W. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00799 · Cited by 560

A biomimetic nanoreactor for synergistic chemiexcited photodynamic therapy and starvation therapy against tumor metastasis

Yu, Z., Zhou, P., Pan, W., Li, N., & Tang, B. (2018) · Nature Communications · doi:10.1038/s41467-018-07197-8 · Cited by 494

Supramolecular cancer nanotheranostics

Zhou, J., Rao, L., Yu, G., Cook, T. R., Chen, X., & Huang, F. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00011f · Cited by 411

The state-of-play and future of platinum drugs

Apps, M. G., Choi, E. H. Y., & Wheate, N. J. (2015) · Endocrine-Related Cancer · doi:10.1530/erc-15-0237 · Cited by 256